Biotech Co.* (Symbol)

Pharma Co. (Symbol/Country)

Type/Product Area

Disclosed Funding (M)

Terms/Details (Month)


Abgenix Inc. (ABGX)

Pfizer Inc. (NYSE:PFE)

Expansion and extension of 12/97 antibody collaboration using Abgenix's XenoMouse technology to generate therapeutic antibodies


Companies extended agreement two years and agreed to include up to two additional antigen targets, raising the total number of possible product candidates to five; Pfizer will be responsible for development, manufacturing and marketing; Abgenix will receive a fee to extend the agreement and could receive research, license and milestone fees, plus royalties (2/00)

Advanced Tissue Sciences Inc. (ATIS)

Smith & Nephew (UK; NYSE: SSN)

Restructuring of 4/96 joint venture (JV) agreement for Dermagraft, ATS' tissue-engineered skin replacement product


Companies agreed to restructure JV as a result of delays in U.S. commercialization of Dermagraft; except for $10M in regulatory approval and reimbursement milestones related to Dermagraft in the treatment of diabetic foot ulcers, ATS has agreed to make all other milestones subject to, and payable from, JV earnings exceeding certain minimum levels; in return, the JV will pay ATS royalties on sales; other than these changes, revenues and expenses will continue to be shared; in addition, ATS will sell its Dermagraft manufacturing assets to a company jointly owned with S&N and also will sell its raw material inventories to the JV; some of those revenues will be used to pay off a loan from S&N (2/00)

Anesta Corp. (NSTA)

Abbott Laboratories (NYSE:ABT)

Renegotiation of U.S. marketing rights under 12/89 agreement covering oral transmucosal products including Actiq, an FDA-approved product for breakthrough cancer pain


Anesta will have primary responsibility for the sales and marketing of Actiq in the U.S; Abbott will continue to manufacture and distribute the product (3/00)

ARIAD Pharmaceuticals Inc. (ARIA)

Aventis Pharmaceuticals Inc. (NYSE:AVE)

Sale to Aventis of joint venture established 3/97 to identify human target genes for drug discovery


ARIAD sold the Hoechst-ARIAD Genomics Center LLC to Aventis for $40M in cash, the return of 3M shares of Series B convertible preferred stock, forgiveness of approximately $2M of long-term debt, drug candidates and related technologies resulting from a four-year osteoporosis collaboration, and the right to use certain technologies developed by the Genomics Center (1/00)

Chromagen Inc.*

Merck & Co. Inc. (NYSE:MRK)

Expansion of 1999 collaboration


Chromagen will use its High Performance Signal Amplification platform technologies and StarBright fluorophores to develop assays for evaluating cell signaling pathways and genes as targets for Merck's drug discovery program (3/00)

Crescendo Pharmaceuticals Corp. (CNDO)

Alza Corp. (NYSE:AZA)

Alza, which created Crescendo in 1997, exercised its option to license Viadur (Duros leuprolide, a once-yearly implant for palliative treatment of advanced prostate cancer)


Alza will make payments based on worldwide sales and retains options to license each Crescendo product and an option to purchase all of the company's Class A common stock (3/00)

Discovery Therapeutics Inc.*

Schwarz Pharma AG (Germany)

Expansion of 1998 agreement for Parkinson Patch SPM-962 (which delivers a novel dopamine agonist) to include Japan


Discovery received a $5M equity investment for the expansion; as with other territories, Schwarz is handling clinical development and marketing (9/00)

Elan Corp. plc (NYSE:ELN)

Wyeth-Ayerst Research (unit of American Home Products Corp.; NYSE:AHP)

New agreement building on 1991-97 collaboration on integrin inhibitors; focus is on small-molecule inhibitors of cell-adhesion molecule Alpha4Beta1 integrin


Elan received an initial payment and could receive additional fees and milestones, as well as royalties on product sales; Elan may opt to co-promote products in the U.S. for a share of operating profits in lieu of royalties (1/00)

Emisphere Technologies Inc. (EMIS)

Novartis Pharma AG (Switzerland)

Execution of option under 12/97 agreement to acquire an exclusive license to develop oral calcitonin for osteoporosis


Emisphere will receive royalties on sales, an up-front fee and potential milestones; Novartis receives exclusive worldwide rights to develop and commercialize, in conjunction with Emisphere, oral salmon calcitonin; Novartis will be responsible for clinical development, marketing and commercialization (2/00)

Novartis Pharma AG (Switzerland)

Extension and expansion of 12/97 collaboration for oral delivery of calcitonin to include second compound


Emisphere will receive a cash payment as a result of the expansion; companies will select a second drug candidate and Novartis will have nine months to exercise an option to acquire an exclusive worldwide option to develop and commercialize the compound; Novartis will pay milestones and royalties on any sales, and will make equity investments at Emisphere's option (3/00)

Geron Corp. (GERN)

Pharmacia & Upjohn (NYSE:PNU)

Exercise of option to extend 3/97 collaboration to discover and develop telomerase inhibitors


Companies extended the research term and compound selection period one additional year to 3/02; Geron will receive additional research funding as part of extension (1/00)

Kyowa Hakko Kogyo Co. (Japan)

Extension of 4/95 collaboration to discover and develop a telomerse inhibitor for treatment of cancer (Asian markets)


Companies extended the research term and compound selection period one additional year to 3/02; Geron will receive additional research funding as part of extension (2/00)

Incyte Genomics (INCY)

Eli Lilly and Co. (NYSE:LLY)

Expansion of 12/96 database subscription agreement


Lilly signed on as the first subscriber to Incyte's single nucleotide polymorphism database and extended its subscription to Incyte's LifeSeq Gold sequence and expression database (1/00)

Abbott Laboratories (NYSE:ABT)

Expansion of 12/95 database subscription agreement


Abbott gains access to Incyte's single nucleotide polymorphism platform (2/00)

Metabasis Therapeutics Inc.*

Sankyo Co. Ltd. (japan)

Extension of 12/97 collaboration on inhibitors of the gluconeogenesis pathway, which is responsible for the over-production of glucose in the liver of patients with Type II diabetes


Metabasis will receive an additional year of research funding, which extends the sponsored research portion of the agreement to 5/01 (2/00)

Myriad Genetics Inc. (MYGN)

Searle (pharmaceutical division of Monsanto Co.; NYSE:MTC)

Expansion of 11/98 collaboration covering use of Myriad's ProNet technologies for drug target discovery


Companies expanded agreement from two to three disease pathways; additional pathway ND; Myriad will receive research funding, license fees and milestone payments of up to $13M, plus royalties (1/00)

Phase-1 Molecular Toxicology*

Boehringer Ingelheim International GmbH (Germany)

Expansion and extension of agreement for toxicological screening of preclinical drug candidates


New agreement adds three years for a total term of six years; Phase-1 will provide molecular and cellular toxicology services, technologies and software (1/00)

Questcor Pharmaceuticals Inc. (AMEX:QSC)

Dainippon Pharmaceutical Co. Ltd. (Japan)

Restructuring of 1/98 agreement; termination of antibacterials collaboration and license agreement for discovery and development of therapeutics using Questcor's ppGpp degradase and peptide deformylase technology


Questcor will receive a $2M up-front payment, milestones and potential royalties; Dainippon gains an exclusive worldwide license for use of the technology to develop pharmaceuticals; Questcor retains the right to co-promote products in Europe and the U.S.; antibacterial research collaboration terminated (2/00)

Sangamo BioSciences Inc.*

Baxter Healthcare Corp. (subsidiary of Baxter International Inc.; NYSE:BAX)

Expansion of 1/00 collaboration to develop and commercialize therapeutics for ischemic cardiovascular and peripheral vascular diseases


Baxter exercised an option to acquire a three-year right of first refusal to Sangamo's future cardiovascular therapeutic candidates based on zinc finger DNA binding proteins; Baxter made an option payment of $7.5M (3/00)

SciClone Pharmaceuticals (SCLN)

Sigma-Tau SpA (Italy)

Expanded 4/99 marketing agreement for Zadaxin, SciClone's immune system enhancer; original agreement gave Sigma-Tau semi-exclusive rights in Italy and Spain, and exclusive rights in Switzerland


Sigma-Tau acquired exclusive development and marketing rights in Europe and will fund the pan-European pivotal Phase III hepatitis C trial of Zadaxin; Sigma-Tau also will fund more than one-third of SciClone's similar U.S. trial; SciClone will receive an up-front equity investment, milestones and revenues from manufacturing Zadaxin (3/00)

Sonus Pharmaceuticals Inc. (SNUS)

Abbott Laboratories (NYSE:ABT)

EchoGen (perflenapent emulsion), an ultrasound contrast agent


Companies modified U.S. marketing agreement to allow the parties to discuss alternative methods of marketing, selling and distributing EchoGen in the U.S. market; Abbott gains option to either market and distribute EchoGen in the U.S. or to terminate existing marketing agreement; option ends 3/31; no payments were made for the modification and none will be made during the period of Abbott's option; if Abbott opts to market EchoGen, the parties have agreed to negotiate an amendment to the existing marketing agreement by 4/30 (2/00)

Trega Biosciences Inc. (TRGA)

Boehringer Ingelheim International GmbH (Germany)

Research collaboration/custom synthesis of solution phase compound libraries


Trega will generate custom libraries for BI's exclusive use; the initial phase of the collaboration is expected to last approximately six months (1/00)


Axys Pharmaceuticals Inc. (AXPH)

Bristol-Myers Squibb Co. (NYSE:BMY)

Termination of 12/97 collaboration to develop inhibitors of hepatitis C protease NS-3


Axys achieved a milestone 9/98, but parties have determined that further pursuit of the HCV protease target would likely not result in a potential therapeutic (2/00)

Hybridon Inc. (OTC BB:HYBN)

G.D. Searle & Co. (unit of Monsanto Co.; NYSE:MTC)

Termination of 1/96 research and development collaboration for antisense compounds; agreement was modified 7/98 to focus on inhibitors of MDM2 oncogene


Hybridon will seek a new development partner for the program; Searle will return all licenses and grant Hybridon use of its own patents related to the agreement; Searle will receive royalties if any compounds discovered in the program are marketed (3/00)

Millennium Pharmaceuticals Inc. (MLNM)

AstraZeneca plc (UK)

Termination of 12/95 collaboration on drug discovery for diseases including asthma, allergic rhinitis, chronic bronchitis and chronic obstructive pulmonary disease


Companies mutually decided to end research phase of collaboration in order to pursue independent research efforts; Millennium received an undisclosed payment and will be entitled to receive milestones and royalties on therapeutic products resulting from targets discovered; Millennium has "complete freedom" to operate in the category of inflammatory respiratory disorders (1/00)

Synaptic Pharmaceutical Corp. (SNAP)

Merck & Co. Inc. (NYSE:MRK)

Termination of 11/93 collaboration on alpha-adrenegic technology


Merck relinquished license to the technology and related patents following Phase IIa trial results involving an alpha-1a antagonist for benign prostatic hyperplasia; Synaptic is seeking other licensees (3/00)


# The information in the chart covers the time period between 1/1/00 and 3/15/00.

* Private companies are indicated with an asterisk

ND = Not disclosed, reported and/or available

AMEX = American Stock Exchange; LSE = London Stock Exchange; NYSE = New York Stock Exchange; OTC BB = Over The Counter Bulletin Board.